---
title: "Is Retatrutide Safe During Menopause?"
description: "Retatrutide has produced substantial weight loss in clinical research, but it remains investigational and its long-term safety is still being evaluated. Gastrointestinal side effects have been reported, while menopause-specific evidence on muscle, bone, and other risks remains limited. For midlife women, the potential effects of substantial weight loss on hydration, nutrition, lean mass, and bone health deserve particular attention."
url: "https://www.myalloy.com/blog/retatrutide-side-effects-guide-to-safety"
---

# Is Retatrutide Safe During Menopause?

*What we know about side effects, risks, and the evidence gaps*

By Alloy Health Editorial Team

## Summary

**Retatrutide side effects** reported in clinical trials include nausea, vomiting, diarrhea, constipation, increased heart rate, altered skin sensation, and less commonly pancreatitis and gallbladder complications; retatrutide remains investigational and is not FDA-approved. For women in **perimenopause and menopause**, substantial weight loss may raise additional concerns about muscle loss, bone density, nutrition, and hydration, making resistance exercise, adequate protein intake, and individualized clinical monitoring important considerations alongside comparisons with approved therapies such as **semaglutide and tirzepatide**.

[Start Your Weight Care Consult](https://secure.myalloy.com/experience?categories%5B%5D=weight-health&sku-ids%5B%5D=6f32bad4-76bd-4b07-8bbd-233c298bb222%2C32f106c4-4054-4f19-a774-dfe9afc12190&skip-category-select=true&type=intake)

You’ve probably heard about GLP-1 medications like [semaglutide](https://www.myalloy.com/solutions/compounded-semaglutide) and [tirzepatide](https://www.myalloy.com/solutions/compounded-tirzepatide). Retatrutide is a newer weight-loss injection that’s still working its way through clinical trials, and it’s getting attention for the substantial weight loss seen in early studies.

Women in perimenopause and menopause aren’t always studied as a separate group in clinical trials, which can leave you wondering what the results mean for you. Here’s what we know so far about retatrutide’s side effects, and how the significant weight loss it can cause may affect women going through menopause.

## How does retatrutide work?

Retatrutide is part of a class of drugs which includes existing GLP-1 therapies such as semaglutide (Ozempic, Wegovy) and [tirzepatide (Zepbound)](https://www.myalloy.com/solutions/zepbound). The currently approved medications in this drug class work by targeting one or two hormone pathways. For example, GLP-1 medications like semaglutide primarily target the GLP-1 receptor, stimulating insulin release, reduced appetite, slowing digestion, and improving control of blood sugar. Tirzepatide, a newer medication, also targets the [GIP receptor](https://doi.org/10.1056/NEJMoa2416394?utm), and it produces greater average weight loss than semaglutide.

Retatrutide is unique. It is a *triple hormone receptor agonist* (“*triple G* *agonist*”) that targets three hormone pathways involved in metabolism:[ GLP-1, GIP, and glucagon](https://doi.org/10.1016/j.cmet.2022.07.013?utm). These hormone systems help to regulate appetite, glucose control, and balance energy. Researchers are studying whether targeting all three pathways may produce greater weight-loss effects than currently approved medications.

## Is Retatrutide FDA-Approved?

Retatrutide is currently in phase 3 clinical trials which are designed to confirm that the drug is safe and effective in larger groups over longer periods of time and to determine if the benefits of its use outweigh the risks. Approval timelines can be complicated and depend on the results of ongoing studies and the outcome of this review process. Until all this research is complete, retatrutide will remain an investigational drug therapy.

 [Reminder or request for the Doctor reviewing - please insert a personal quote here, or anywhere you see fit based on your experience. Example “We have found that after 3 months of hormone therapy, patients experience….etc.] 

## What side effects have retatrutide trials found?

Retatrutide’s side effects are similar to those experienced with semaglutide and tirzepatide. During [phase 2 clinical trials](https://pubmed.ncbi.nlm.nih.gov/37366315/) for retatrutide, the main side effects reported were gastrointestinal and included nausea, vomiting, diarrhea, and constipation. These symptoms appeared to be mild or moderate and occurred most often when doses were being increased or for patients using higher doses.

Researchers also observed increases in heart rate, changes in heart rhythm, and increased skin sensitivity in some participants. Less commonly reported were some potentially serious problems, including pancreatitis and gallbladder complications. Larger clinical trials will help researchers better understand the frequency and severity of these adverse effects and identify potential longer-term risks.

[More recent phase 3 research](https://pubmed.ncbi.nlm.nih.gov/42810372/) in adults with obesity and type 2 diabetes has also reported gastrointestinal side effects, along with low blood pressure and altered skin sensation. Although these findings provide additional safety information, longer-term risks and potential differences in women going through menopause remain uncertain. 

In the [phase 2 obesity trial](https://www.nejm.org/doi/full/10.1056/NEJMoa2301972), participants receiving higher doses lost an average of up to approximately 24% of their body weight over 48 weeks. While these results are promising, substantial weight loss also raises questions about nutrition, muscle preservation, and bone health, particularly during menopause.

## Why does menopause change the safety conversation for women?

During the transition to menopause, estrogen levels fall, causing bone loss to accelerate. At the same time these same hormonal changes combined with natural aging cause a decrease in muscle mass and strength during midlife.

This is especially important when considering medications that can produce substantial weight loss. Typically weight loss will include both fat and muscle tissue as well. For women who may already be experiencing changes in muscle strength and bone density, additional muscle loss can have a negative impact.  

Muscle strength helps maintain balance, mobility, and independence as we age. Reduced strength is associated with a greater risk of falls and disability, while low bone density increases the likelihood that a fall will result in a fracture. Severe muscle impairment is also associated with increased mortality. Preserving muscle during weight loss is therefore an important part of protecting long-term health, particularly during and after menopause.

## Are muscle, bone, and nutrition risks preventable?


The aim of weight loss treatment is better health overall, which includes keeping your bones strong and staying mobile.

Resistance and weight-bearing exercise help provide mechanical support to help preserve bone mineral density and lean muscle mass. Both of these are  important for improving balance and reducing fall risk. The American Board of Obesity Medicine (ABOM) recommends 150-300 minutes of moderate exercise per week, including two days of strength training. Consuming adequate amounts of dietary protein can help preserve lean muscle during weight loss, as well as calcium, vitamin D, and vitamin K2 for the support of normal bone health.

Women with existing osteoporosis risk factors or substantial weight loss may benefit from individualized bone-health assessment, including bone density testing when clinically indicated.

The gastrointestinal symptoms commonly experienced with medications like retatrutide can also make it difficult to maintain adequate nutrition and hydration. When nausea, vomiting, or diarrhea interfere with normal eating and drinking, maintaining fluid intake and discussing persistent symptoms with a clinician become especially important.

## How does retatrutide compare with semaglutide and tirzepatide?

[Semaglutide](https://www.myalloy.com/solutions/compounded-semaglutide) and [tirzepatide](https://www.myalloy.com/solutions/compounded-tirzepatide) have more established safety profiles because they have been evaluated in larger clinical development programs and are used in routine medical practice.

Both medications are well-known for causing gastrointestinal symptoms, especially when treatment is first begun or when doses are escalated. Their prescribing information also includes warnings and precautions involving conditions such as pancreatitis, gallbladder disease, and kidney injury associated with dehydration.

Although these established risks provide useful context when evaluating newer medications, we cannot assume they will be the same for retatrutide. We do not yet know if it will have the same long-term risks and side effects.

For women considering medication-assisted weight management now, approved treatments offer more established information about expected benefits, adverse effects, and appropriate patient selection.

## What should you discuss with your doctor?


Managing weight in midlife often takes a different strategy than it did in earlier decades. Retatrutide is a promising investigational therapy, but if you’re interested in weight-loss medication, there are established options you can talk to your doctor about now.

If retatrutide caught your eye, tell your doctor what appealed to you—whether it’s the amount of weight loss, the dosing, or something else. They can walk you through which established options come closest and what to expect. Bring up your health history, other medications, and which side effects concern you most, and ask how you’ll protect your muscle and bones, how your progress will be tracked, and what the plan is if you plateau or want to stop.

## Getting care for weight and menopause together

If you are already using an approved weight-loss medication, a doctor can also review the prescribed dose, other medications, and relevant medical conditions to determine whether treatment adjustments are needed.

If menopause symptoms are also affecting your health or quality of life, talk with your doctor about those specifically. A GLP-1 will not treat the hormonal symptoms of menopause, but other therapies can help. A doctor experienced in menopause care can help you understand your options and how they may fit together.

Alloy Health connects you with a board-certified, menopause-specialized doctor who can look at weight management and your other menopause symptoms together, with your health history and current treatments in mind.

---

## Frequently Asked Questions


### How does retatrutide work, and is it FDA-approved?

Retatrutide is an investigational triple hormone receptor agonist, or "triple G agonist," that targets three metabolic hormone pathways—GLP-1, GIP, and glucagon—to help regulate appetite, glucose control, and energy balance. Unlike semaglutide, which primarily targets one pathway, and tirzepatide, which targets two, retatrutide acts on all three and produced an average weight loss of up to approximately 24% of body weight over 48 weeks in a phase 2 obesity trial. However, retatrutide is not yet FDA-approved; it remains an investigational therapy currently undergoing phase 3 clinical trials to confirm its long-term safety and effectiveness.

### What side effects have been reported in retatrutide clinical trials?

Similar to semaglutide and tirzepatide, the primary side effects seen in retatrutide trials are mild-to-moderate gastrointestinal symptoms, including nausea, vomiting, diarrhea, and constipation, which occur most often during dose increases or at higher doses. Researchers have also observed increases in heart rate, heart rhythm changes, low blood pressure, and increased skin sensitivity or altered skin sensation in some participants. Less commonly, potentially serious complications such as pancreatitis and gallbladder problems have been reported, and longer-term risks—particularly for women going through menopause—remain uncertain.

### Why does menopause change the safety conversation around retatrutide, and how can muscle and bone risks be managed?

Declining estrogen levels and natural aging during the menopause transition accelerate bone loss and reduce muscle mass and strength. Because substantial weight loss typically involves losing both fat and muscle tissue, additional muscle loss in midlife can increase the risk of falls, fractures, and disability. To protect bone mineral density and lean muscle mass during weight loss, experts recommend getting adequate dietary protein along with calcium, vitamin D, and vitamin K2, and completing 150–300 minutes of moderate exercise per week, including two days of resistance and weight-bearing strength training. Women with osteoporosis risk factors or significant weight loss may also benefit from bone density testing and maintaining fluid intake if gastrointestinal side effects interfere with eating and drinking.

---

## References


1. Jastreboff AM, Kaplan LM, Frías JP, et al; Retatrutide Phase 2 Obesity Trial Investigators. Triple–hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023;389(6):514-526. doi:[10.1056/NEJMoa2301972](https://doi.org/10.1056/NEJMoa2301972?utm_source=chatgpt.com)

2. Bellido V, le Roux CW, Ekinci EI, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. Published online September 29, 2026. doi:[10.1016/S0140-6736(26)01861-1](https://doi.org/10.1016/S0140-6736(26)01861-1?utm_source=chatgpt.com)

3. Coskun T, Wu Q, Schloot NC, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol. 2025;13(8):674-684. doi:[10.1016/S2213-8587(25)00092-0](https://doi.org/10.1016/S2213-8587(25)00092-0?utm_source=chatgpt.com)

4. Lee Y, Oh B. Clinical evaluation and treatment of obesity in women across selected life stages: a narrative review. Womens Health Nurs. 2026;32(3):180-189. doi:[10.4069/whn.2026.09.02](https://doi.org/10.4069/whn.2026.09.02?utm_source=chatgpt.com)

5. Greendale GA, Sternfeld B, Huang M, et al. Changes in body composition and weight during the menopause transition. JCI Insight. 2019;4(5):e124865. doi:[10.1172/jci.insight.124865](https://doi.org/10.1172/jci.insight.124865?utm_source=chatgpt.com)

6. Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity (Silver Spring). 2025;33(8):1475-1503. doi:[10.1002/oby.24336](https://doi.org/10.1002/oby.24336?utm_source=chatgpt.com)

7. LeBoff MS, Greenspan SL, Insogna KL, et al. The clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022;33:2049-2102. doi:[10.1007/s00198-021-05900-y](https://doi.org/10.1007/s00198-021-05900-y?utm_source=chatgpt.com)

8. Wilding JPH, Batterham RL, Calanna S, et al; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:[10.1056/NEJMoa2032183](https://doi.org/10.1056/NEJMoa2032183?utm_source=chatgpt.com)

9. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. doi:[10.1056/NEJMoa2206038](https://doi.org/10.1056/NEJMoa2206038?utm_source=chatgpt.com)

## Related Content

1. [https://www.myalloy.com/blog/what-is-retatrutide-and-when-and-how-to-try-it](https://www.myalloy.com/blog/what-is-retatrutide-and-when-and-how-to-try-it)
2. [https://www.myalloy.com/blog/are-glp-1-medications-safe-and-what-about-side-effects](https://www.myalloy.com/blog/are-glp-1-medications-safe-and-what-about-side-effects)
3. [https://www.myalloy.com/blog/is-microdosing-tirzepatide-safe](https://www.myalloy.com/blog/is-microdosing-tirzepatide-safe)
4. [https://www.myalloy.com/blog/starting-your-weight-care-journey](https://www.myalloy.com/blog/starting-your-weight-care-journey)
5. [https://www.myalloy.com/blog/menopause-protective-protocol-for-glp-1-weight-loss](https://www.myalloy.com/blog/menopause-protective-protocol-for-glp-1-weight-loss)
6. [https://www.myalloy.com/blog/what-is-a-good-menopause-diet-plan-how-many-grams-of-protein-are-needed](https://www.myalloy.com/blog/what-is-a-good-menopause-diet-plan-how-many-grams-of-protein-are-needed)
7. [https://www.myalloy.com/blog/peptide-therapy-during-menopause](https://www.myalloy.com/blog/peptide-therapy-during-menopause)

## Citations

1. Yongho Lee, Bumjo Oh. Clinical evaluation and treatment of obesity in women across selected life stages: a narrative review. Womens Health Nurs 2026;32(3):180-189. doi:10.4069/whn.2026.09.02. PMC:PMC13654666. PMID:42860281. — [View source](https://www.e-whn.org/journal/view.php?doi=10.4069/whn.2026.09.02)
2. Andreas B Jordy, Muna Albayaty, Astrid Breitschaft, Thomas W Anderson, Erik Christiansen, Azadeh Houshmand-Øregaard, et al.. Effect of Oral Semaglutide on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women and Furosemide and Rosuvastatin in Healthy Subjects. Clin Pharmacokinet 2021;60(9):1171-1185. doi:10.1007/s40262-020-00976-x. PMC:PMC8416862. PMID:33782832. — [View source](https://pmc.ncbi.nlm.nih.gov/articles/pmid/33782832/)
3. Maneeha Naveed, Cecilie Perez, Ehtasham Ahmad, Laura Russell, Zoe Lees, Catriona Maybury. GLP-1 medication and weight loss: Barriers and motivators among 1659 participants managed in a virtual setting. Diabetes Obes Metab 2025;27(7):3780-3788. PMID:40259493. — [View source](https://doi.org/10.1111/dom.16405)
4. Betsy S Thomas, Danielle Perry, Samantha S Moe, Ricky D Turgeon, Jen Potter, Émélie Braschi, et al.. Top studies of 2023 relevant to primary care: From the PEER team. Can Fam Physician 2024;70(4):245-248. doi:10.46747/cfp.7004245. PMC:PMC11280662. PMID:38626998. — [View source](http://www.cfp.ca/cgi/pmidlookup?view=long&pmid=38626998)

---

*This is a markdown version of [https://www.myalloy.com/blog/retatrutide-side-effects-guide-to-safety](https://www.myalloy.com/blog/retatrutide-side-effects-guide-to-safety) for AI/LLM consumption.*